Keros Therapeutics (KROS) Misses Q4 EPS by 134c

Keros Therapeutics (NASDAQ: KROS) reported Q4 EPS of ($1.34), $1.34 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $140 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• TD Cowen Reiterates Buy Rating on NVIDIA (NVDA), 'unlikely to move significantly on earnings'
• 374Water Inc (SCWO) Misses Q2 EPS by 15c